Estimation of the dry weight of a dialysis patient

Patent metadata

Field	Value
Publication number	US-10953147-B2
Application number	US-201715591973-A
Country	US
Kind code	B2
Filing date	May 10, 2017
Priority date	Sep 19, 2011
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

In an embodiment, the invention relates to methods, apparatus, computer programs and computer program products for estimating a dry weight of a dialysis patient comprising the steps of determining a first fluid status of the patient between treatment sessions in a first stage, determining a second fluid status of the patient during treatment sessions in a second stage and estimating the dry weight based on the second fluid status.

First claim

What is claimed is:

1. A method for estimating a dry weight of a dialysis patient comprising:
determining a current fluid status of the dialysis patient;
determining that the dialysis patient is in a first stage (I) if the current fluid status indicates a severe fluid overload;
determining that the dialysis patient is in a second stage (II) if the current fluid status indicates a fluid overload within a range of a normal fluid status;
determining a first fluid status of the dialysis patient between dialysis treatment sessions during the first stage (I);
determining a second fluid status of the dialysis patient during dialysis treatment sessions during the second stage (II), wherein the second fluid status is an intradialytic fluid status determined based on a continuously monitored evolution of a fluid status during a dialysis treatment session by at least one of a blood volume measurement method and segmental bioimpedance spectroscopy (BIS); and
estimating the dry weight based on the second fluid status, the estimating comprising at least one of analysis of a resistance curve, a normalized resistivity, or a relative blood volume.

2. The method according to claim 1 , wherein the first fluid status is determined by a pre-treatment session measurement.

3. The method according to claim 1 , wherein the first fluid status is determined by a post-treatment session measurement.

4. The method according to claim 3 , wherein the first fluid status is determined by at least one of:
a) a physical examination method,
b) an imaging method,
c) biochemical markers,
d) a thermal dilution determination method,
e) a bioimpedance measurement method,
f) the ratio between the total body water volume (TBW) and the extracellular water volume (ECV), and
g) a blood volume measurement method.

5. The method according to claim 1 , further comprising estimating the normal fluid status based on the first fluid status.

6. The method according to claim 1 , wherein the range of the normal fluid status comprises about 2.5 to about 0.25 L within an estimated normal fluid status of the dialysis patient.

7. The method according to claim 6 , wherein the normal fluid status and/or weight (NFSW w ms) is estimated by a whole body model or by a calf normalized resistivity (CNR) method.

8. The method according to claim 7 , wherein the second stage (II) starts if a blood volume monitoring shows that the relative blood volume (RB V) decreases during a dialysis treatment session.

9. The method according to claim 1 , wherein the first stage (I) lasts approximately 1 to 6 months.

10. The method according to claim 9 , wherein the first fluid status is determined periodically.

11. The method according to claim 1 , wherein the second fluid status is determined during every treatment session.

12. The method according to claim 1 , wherein the dry weight of the dialysis patient is reached if a flattening of the resistance curve of the dialysis patient recorded during a treatment session in the second stage (II) is reached and/or the normalized resistivity of the dialysis patient is within a normal post-hemodialytic range of a comparison group.

13. The method according to claim 12 , wherein the resistance is measured by calf bioimpedance spectroscopy and/or the normalized resistivity of the dialysis patient is the normalized calf resistivity.

14. The method according to claim 1 , wherein the severe fluid overload comprises a fluid overload greater than about 2.5 liters to about 0.2 liters of an estimated normal fluid status of the dialysis patient.

15. The method according to claim 1 , wherein the first fluid status is an interdialytic fluid status determined based on an intermittent measurement.

16. The method according to claim 15 , wherein the intermittent measurement is determined by a non-continuous measurement without electrodes on the patient.

17. The method according to claim 15 , wherein the intermittent measurement does not include a blood volume measurement method or segmental bioimpedance spectroscopy (BIS).

18. An apparatus, comprising
at least one processor; and
a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the at least one processor, cause the at least one processor to:
receive a first fluid status of a dialysis patient during a first stage (I), wherein the dialysis patient is in the first stage (I) if a current fluid status indicates a severe fluid overload, the first fluid status comprising an interdialytic fluid status measured using an intermittent measurement method,
receive a second fluid status of the dialysis patient during a second stage (II), wherein the dialysis patient is in second stage (II) if the current fluid status indicates a fluid overload within a range of a normal fluid status, the second fluid status comprising an intradialytic fluid status measured using an continuous measurement method during a dialysis session, and
estimating the dry weight based on the second fluid status.

19. The apparatus according to claim 18 , the instructions, when executed by the at least one processor, cause the at least one processor to determine a dosage of at least one of a medicament, an antibiotic, and a parenterally-administered drug based on at least one of the first fluid status and the second fluid status.

20. The apparatus according to claim 18 , the instructions, when executed by the at least one processor, cause the at least one processor to estimate the normal fluid status based on the first fluid status.

21. The apparatus according to claim 18 , wherein the severe fluid overload comprises a fluid overload greater than about 2.5 liters to about 0.2 liters of an estimated normal fluid status of the dialysis patient.

22. The apparatus according to claim 18 , wherein the range of the normal fluid status comprises about 2.5 to about 0.25 L within an estimated normal fluid status of the dialysis patient.

23. The apparatus according to claim 18 , wherein the second stage (II) starts if a blood volume monitoring shows that the relative blood volume (RB V) decreases during a dialysis treatment session.

Assignees

• Fresenius Medical Care Holdings Inc
• Fresenius Medical Care Deutschland Gmbh

Inventors

• Levin Nathan W
• Zhu Fansan
• Kotanko Peter
• Wabel Peter
• Tetta Ciro

Classifications

• A61M1/1613

  Profiling or modelling of patient or predicted treatment evolution or outcome · CPC title

• A61B5/0537

  Measuring body composition by impedance, e.g. tissue hydration or fat content · CPC title

• A61M2230/65

  Impedance, e.g. conductivity, capacity · CPC title

• A61M2205/3317

  Electromagnetic, inductive or dielectric measuring means · CPC title

• A61M1/16 Primary

  with membranes · CPC title